BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Agenus Inc.
• 

  FogPharma
• 

  Nimbus Therapeutics
• 

  Nona Biosciences
• 

  Mural Oncology
• 

  Astria Therapeutics
• 

  Organogenesis Inc
• 

  Mergers & acquisitions

  Unions, Public Interest Groups Call on FTC to Challenge Novo Holdings-Catalent Acquisition

  Pressure has been mounting for the Federal Trade Commission to take action, with Senator Elizabeth Warren last week urging FTC Chair Lina Khan to block the merger if it violates antitrust laws.

  October 18, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  RSV

  Merck, Pfizer Tout Promising Respective Data in RSV With High Rates of Prevention

  Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory syncytial virus-associated infections in infants, while Pfizer’s RSV vaccine Abrysvo showed 90% effectiveness at preventing the most severe RSV cases in adults 60 years and older.

  October 18, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Regulatory

  FDA Pushes Back PDUFA Dates for Amgen and Intercept

  The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic colorectal cancer and Intercept Pharmaceuticals’ Ocaliva for primary biliary cholangitis.

  October 18, 2024

   · 

  2 min read

   · 

  Tristan Manalac